Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a r
about
Diagnostic challenges of kidney diseases in HIV-infected patients.Bone mineral density optimisation in adults with perinatally acquired HIV infection in routine care.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
P2860
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a r
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Efficacy and safety of emtrici ...... analysis by third agent of a r
@en
type
label
Efficacy and safety of emtrici ...... analysis by third agent of a r
@en
prefLabel
Efficacy and safety of emtrici ...... analysis by third agent of a r
@en
P2093
P2860
P1433
P1476
Efficacy and safety of emtrici ...... controlled phase 3 trial<sup/>
@en
P2093
Andrew Cheng
Cecilia Tran-Muchowski
Franco Maggiolo
Frank A Post
Gabriel Schembri
Jacques Reynes
Martin S Rhee
Mingjin Yan
Yazdan Yazdanpanah
P2860
P304
P356
10.1080/15284336.2017.1291867
P577
2017-03-17T00:00:00Z